医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Announces Second Installation in Hong Kong

2015年09月24日 PM07:30
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today that The Duchess of Kent Children’s Hospital has become the second hospital in Hong Kong to install the EOS® platform. The center’s stellar reputation for treating pediatric orthopedic and spinal surgeries is reinforced by their commitment to use the latest technologies while minimizing the radiation exposure for their patients.

The hospital was founded in 1955 by the Society for the Relief of Disabled Children and is now part of the highly ranked Hong Kong University Hospital network. The ability to visualize patient anatomy in 3D played an important role in the hospital’s decision to rely on EOS for diagnosis, treatment planning and control.

Professor Kenneth Cheung, Head of Department of Orthopedics and Traumatology at The University of Hong Kong, and Director of the Early Onset Scoliosis Surgery program at The Duchess of Kent Children’s Hospital, commented, “As part of our ongoing efforts to provide the best pediatric orthopedic care for our patients, we are excited to announce the installation of the EOS platform. The system will allow us to provide the frequent scans that our patients require, while the low-dose radiation will help prevent future health problems as the children grow.”

The EOS platform provides 2D and 3D full-body, stereo-radiographic images of patients in functional positions. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose system, recently cleared by the Food and Drug Administration, marks another important step towards the ALARA principle (As Low As Reasonably Available). This latest technology has made the dose for a pediatric spine follow-up exam equivalent to a week of natural background radiation on Earth.

Marie Meynadier, CEO of EOS imaging, said, “We are thrilled to see the continued expansion of EOS systems in Asia. It’s always exciting when a highly-ranked institution such as the Duchess of Kent Children’s Hospital in Hong Kong adopts the technology knowing that so many more patients will benefit from the unique attributes of the EOS platform.”

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3rd quarter of 2015, on October 19, 2015 (after market).

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2014 revenues of €20.1 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150924005526/en/

CONTACT

EOS imaging
Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Pierre
Laurent, +33 (0)1 44 71 94 91
Financial communication and investor
relations
eosimaging@newcap.fr
or
The
Ruth Group (US)

Joanna Zimmerman, 646-536-7006
Press
relations
jzimmerman@theruthgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402